Trial NCT04640402
Publication Meng F-Y, Signal Transduct Tar, 2021
Primary outcome on the report: 1. GMT of RBD-specific ELISA antibody responses at 30 days after the last dose vaccination. 2. The incidence of adverse reactions within 7 days after each dose vaccination.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.